We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's How Much You'd Have If You Invested $1000 in Acadia Pharmaceuticals a Decade Ago
Read MoreHide Full Article
For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and industries.
The fear of missing out, or FOMO, also plays a factor in investing, especially with particular tech giants, as well as popular consumer-facing stocks.
What if you'd invested in Acadia Pharmaceuticals (ACAD - Free Report) ten years ago? It may not have been easy to hold on to ACAD for all that time, but if you did, how much would your investment be worth today?
Acadia Pharmaceuticals' Business In-Depth
With that in mind, let's take a look at Acadia Pharmaceuticals' main business drivers.
San Diego, CA-based ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative medicines to address the unmet medical needs in central nervous system (CNS) disorders.
The company’s sole marketed drug Nuplazid (pimavanserin) is the first and the only Food and Drug Administration (FDA)-approved treatment for hallucinations and delusions associated with Parkinson’s disease (PD) psychosis. The drug was launched in May 2016. ACADIA’s top-line consists of only net product sales of Nuplazid in the United States.
A supplemental new drug application (sNDA) seeking approval of Nuplazid for dementia-related psychosis has been filed in the United States. In April 2021, the company suffered a setback, when the FDA issued a complete response letter (CRL) to Nuplazid sNDA for the given indication.
Notably, several additional studies on Nuplazid n targeting different CNS indications, such as dementia-related psychosis, schizophrenia inadequate response, schizophrenia negative symptoms and as an adjunctive treatment of major depressive disorder (MDD) are currently underway.
Meanwhile, in August 2018, ACADIA entered into a license agreement with Australian biopharmaceutical company Neuren Pharmaceuticals Limited and obtained exclusive North American rights to develop and commercialize trofinetide for Rett syndrome and other indications.
ACADIA’s top line mainly comprises U.S. sales of Nuplazid. The company recognized revenues worth $441.7 million in 2020 compared with $339.1 million in 2019.
Bottom Line
Anyone can invest, but building a successful investment portfolio requires research, patience, and a little bit of risk. So, if you had invested in Acadia Pharmaceuticals ten years ago, you're likely feeling pretty good about your investment today.
According to our calculations, a $1000 investment made in May 2011 would be worth $11,515.46, or a gain of 1,051.55%, as of May 31, 2021, and this return excludes dividends but includes price increases.
In comparison, the S&P 500 gained 215.84% and the price of gold went up 19.21% over the same time frame.
Analysts are forecasting more upside for ACAD too.
ACADIA’s earnings beat estimates while its revenues missed the same in Q1. The company’s sole marketed drug, Nuplazid, recorded strong sales since its launch. The drug’s label-expansion program also looks promising, with several studies targeting various disorders currently underway. The company is also developing Nuplazid to treat other neuropsychiatric conditions. If approved, not only will the drug’s eligible patient population be expanded, but sales will be driven higher in 2021. However, heavy dependence on Nuplazid for revenues remains a woe. Moreover, the recent regulatory setback wherein the FDA issued a complete response letter for Nuplazid label expansion hurt the stock severely. Stiff competition is also a concern. Shares have underperformed the industry year to date.
The stock has jumped 8.66% over the past four weeks. Additionally, no earnings estimate has gone lower in the past two months, compared to 11 higher, for fiscal 2021; the consensus estimate has moved up as well.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's How Much You'd Have If You Invested $1000 in Acadia Pharmaceuticals a Decade Ago
For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and industries.
The fear of missing out, or FOMO, also plays a factor in investing, especially with particular tech giants, as well as popular consumer-facing stocks.
What if you'd invested in Acadia Pharmaceuticals (ACAD - Free Report) ten years ago? It may not have been easy to hold on to ACAD for all that time, but if you did, how much would your investment be worth today?
Acadia Pharmaceuticals' Business In-Depth
With that in mind, let's take a look at Acadia Pharmaceuticals' main business drivers.
San Diego, CA-based ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative medicines to address the unmet medical needs in central nervous system (CNS) disorders.
The company’s sole marketed drug Nuplazid (pimavanserin) is the first and the only Food and Drug Administration (FDA)-approved treatment for hallucinations and delusions associated with Parkinson’s disease (PD) psychosis. The drug was launched in May 2016. ACADIA’s top-line consists of only net product sales of Nuplazid in the United States.
A supplemental new drug application (sNDA) seeking approval of Nuplazid for dementia-related psychosis has been filed in the United States. In April 2021, the company suffered a setback, when the FDA issued a complete response letter (CRL) to Nuplazid sNDA for the given indication.
Notably, several additional studies on Nuplazid n targeting different CNS indications, such as dementia-related psychosis, schizophrenia inadequate response, schizophrenia negative symptoms and as an adjunctive treatment of major depressive disorder (MDD) are currently underway.
Meanwhile, in August 2018, ACADIA entered into a license agreement with Australian biopharmaceutical company Neuren Pharmaceuticals Limited and obtained exclusive North American rights to develop and commercialize trofinetide for Rett syndrome and other indications.
ACADIA’s top line mainly comprises U.S. sales of Nuplazid. The company recognized revenues worth $441.7 million in 2020 compared with $339.1 million in 2019.
Bottom Line
Anyone can invest, but building a successful investment portfolio requires research, patience, and a little bit of risk. So, if you had invested in Acadia Pharmaceuticals ten years ago, you're likely feeling pretty good about your investment today.
According to our calculations, a $1000 investment made in May 2011 would be worth $11,515.46, or a gain of 1,051.55%, as of May 31, 2021, and this return excludes dividends but includes price increases.
In comparison, the S&P 500 gained 215.84% and the price of gold went up 19.21% over the same time frame.
Analysts are forecasting more upside for ACAD too.
ACADIA’s earnings beat estimates while its revenues missed the same in Q1. The company’s sole marketed drug, Nuplazid, recorded strong sales since its launch. The drug’s label-expansion program also looks promising, with several studies targeting various disorders currently underway. The company is also developing Nuplazid to treat other neuropsychiatric conditions. If approved, not only will the drug’s eligible patient population be expanded, but sales will be driven higher in 2021. However, heavy dependence on Nuplazid for revenues remains a woe. Moreover, the recent regulatory setback wherein the FDA issued a complete response letter for Nuplazid label expansion hurt the stock severely. Stiff competition is also a concern. Shares have underperformed the industry year to date.
The stock has jumped 8.66% over the past four weeks. Additionally, no earnings estimate has gone lower in the past two months, compared to 11 higher, for fiscal 2021; the consensus estimate has moved up as well.